Anti-Inflammation, Immunomodulation and Therapeutic Repair in Current Clinical Trials for the Management of COVID-19

References

• WangD, HuB, HuC, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi:10.1001/jama.2020.158532031570
   PubMed Web of Science ®Google Scholar
• World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccine. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 319, 2021.
   Google Scholar
• OliverSE, GarganoJW, MarinM, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Pfizer-BioNTech COVID-19 vaccine – United States. MMWR Morb Mortal Wkly Rep. 2020;69:1922–1924. doi:10.15585/mmwr.mm6950e233332292
   PubMed Web of Science ®Google Scholar
• OliverSE, GarganoJW, MarinM, et al. The Advisory Committee on Immunization Practices’ interim recommendation for use of Moderna COVID-19 vaccine – United States, December 2020. MMWR Morb Mortal Wkly Rep. 2021;69:1653–1656. doi:10.15585/mmwr.mm695152e133382675
   PubMed Web of Science ®Google Scholar
• HuangC, WangY, LiX, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-531986264
   PubMed Web of Science ®Google Scholar
• AoubaA, BaldolliA, GeffrayL, et al. Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis Month. 2020;79:1381–1382. doi:10.1136/annrheumdis-2020-217706
   PubMed Web of Science ®Google Scholar
• The CORIMUNO-19 Collaborative group. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021. doi:10.1016/S2213-2600(20)30556-7
   Web of Science ®Google Scholar
• XuX, HanM, LiT, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117:10970–10975. doi:10.1073/pnas.200561511732350134
   PubMed Web of Science ®Google Scholar
• RossottiR, TraviG, UghiN, et al. Safety and efficacy of anti-IL6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis. J Infect. 2020;81:e11–e17. doi:10.1016/j.jinf.2020.07.008
   PubMed Web of Science ®Google Scholar
• SalamaC, HanJ, YauL, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30. doi:10.1056/NEJMoa203034033332779
   PubMed Web of Science ®Google Scholar
• StoneJH, FrigaultMJ, Serling-BoydNJ, et al. Efficacy of Tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–2344. doi:10.1056/NEJMoa202883633085857
   PubMed Web of Science ®Google Scholar
• SchwartzDM, KannoY, VillarinoA, WardM, GadinaM, O’SheaJJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16:843–862. doi:10.1038/nrd.2017.20129104284
   PubMed Web of Science ®Google Scholar
• MilaraJ, HernandezG, BallesterB, et al. The JAK2 pathway is activated in idiopathic pulmonary fibrosis. Respir Res. 2018;19:24. doi:10.1186/s12931-018-0728-929409529
   PubMed Web of Science ®Google Scholar
• RichdsonP, GriffinI, TuckerC, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395:e30–e31. doi:10.1016/S0140-6736(20)30304-432032529
   PubMed Web of Science ®Google Scholar
• StebbingJ, PhelanA, GriffinI, et al. COVID-19: combining antiviral and anti-inflammatory treatment. Lancet Infect Dis. 2020;20:400–402. doi:10.1016/S1473-3099(20)30132-832113509
   PubMed Web of Science ®Google Scholar
• KalilAC, PattersonTF, MehtaAK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2020. doi:10.1056/NEJMoa2031994
   Web of Science ®Google Scholar
• La RoséeF, BremerHC, GehrkeI, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–1815. doi:10.1038/s41375-020-0891-032518419
   PubMed Web of Science ®Google Scholar
• FavalliEG, BiggioggeroM, MaioliG, CaporaliR. Baricitinib for COVID-19: a suitable treatment? Lancet Infect Dis. 2020;20:1012–1013. doi:10.1016/S1473-3099(20)30262-0
   PubMed Web of Science ®Google Scholar
• MehtaP, CiurtinC, ScullyM, LeviM, ChambersRC. JAK inhibitors in COVID-19: need for vigilance regarding increased inherent thrombotic risk. Eur Respir J. 2020;56:2001919.32631841
   PubMed Web of Science ®Google Scholar
• AppelbergS, GuptaS, Svensson AkusjärviS, et al. Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteo-transcriptomics of SARS-CoV-2 infected cells. Emerg Microbes Infect. 2020;9:1748–1760. doi:10.1080/22221751.2020.179972332691695
   PubMed Web of Science ®Google Scholar
• KindrachukJ, OrkB, HartBJ, et al. Antiviral potential of ERK/MAPK and PI3K/AKT/mTOR signaling modulation for Middle East respiratory syndrome coronavirus infection as identified by temporal kinome analysis. Antimicrob Agents Chemother. 2015;59:1088–1099. doi:10.1128/AAC.03659-1425487801
   PubMed Web of Science ®Google Scholar
• DuanK, LiuB, LiC, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci USA. 2020;117:9490–9496. doi:10.1073/pnas.200416811732253318
   PubMed Web of Science ®Google Scholar
• XiaX, LiK, WuL, et al. Improved clinical symptoms and mortality on severe/critical COVID-19 patients utilizing convalescent plasma transfusion. Blood. 2020;136:755–759. doi:10.1182/blood.202000707932573724
   PubMed Web of Science ®Google Scholar
• HegerovaL, GooleyTA, SweerusKA, et al. Use of convalescent plasma in hospitalized patients with COVID-19: case series. Blood. 2020;136:759–762. doi:10.1182/blood.202000696432559767
   PubMed Web of Science ®Google Scholar
• LiL, ZhangW, HuY, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460–470. doi:10.1001/jama.2020.1004432492084
   PubMed Web of Science ®Google Scholar
• RojasM, RodríguezY, MonsalveDM, et al. Convalescent plasma in Covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19:102554. doi:10.1016/j.autrev.2020.10255432380316
   PubMed Web of Science ®Google Scholar
• LvH, WuNC, TsangOT, et al. Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections. Cell Rep. 2020;31:107725. doi:10.1016/j.celrep.2020.107725
   PubMed Web of Science ®Google Scholar
• IwasakiA, YangY. The potential danger of suboptimal antibody responses in COVID-19. Nat Rev Immunol. 2020;20:339–341. doi:10.1038/s41577-020-0321-632317716
   PubMed Web of Science ®Google Scholar
• Alijotas-ReigJ, Esteve-ValverdeE, BeliznaC, et al. Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: a comprehensive review. Autoimmun Rev. 2020;19:102569. doi:10.1016/j.autrev.2020.10256932376394
   PubMed Web of Science ®Google Scholar
• RamanRS, BargeVB, DarivenulaAK, et al. A phase II safety and efficacy study on prognosis of moderate pneumonia in COVID-19 patients with regular intravenous immunoglobulin therapy. J Infect Dis. 2021. doi:10.1093/infdis/jiab098
   Web of Science ®Google Scholar
• ShaoZ, FengY, ZhongL, et al. Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID-19: a multicenter retrospective cohort study. Clin Transl Immunol. 2020;9:e1192. doi:10.1002/cti2.1192
   PubMed Web of Science ®Google Scholar
• Lilly. Lilly begins world’s first study of a potential COVID-19 antibody treatment in humans. Available from: https://investor.lilly.com/news-releases/news-release-details/lilly-begins-worlds-first-study-potential-covid-19-antibody. Accessed 319, 2021.
   Google Scholar
• KuZ, XieX, DavidsonE, et al. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. Nat Commun. 2021;12:469. doi:10.1038/s41467-020-20789-733473140
   PubMed Web of Science ®Google Scholar
• ZhangC, WangY, ZhuY, et al. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nat Commun. 2021;12:264. doi:10.1038/s41467-020-20465-w33431876
   PubMed Web of Science ®Google Scholar
• WeinreichDM, SivapalasingamS, NortonT, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Eng J Med. 2021;384:238–251.
   PubMed Web of Science ®Google Scholar
• RisitanoAM, MastellosDC, Huber-LangM, et al. Complement as a target in COVID-19? Nat Rev Immunol. 2020;20:343–344. doi:10.1038/s41577-020-0320-732327719
   PubMed Web of Science ®Google Scholar
• GralinskiLE, SheahanTP, MorrisonTE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio. 2018;9:e01753. doi:10.1128/mBio.01753-1830301856
   PubMed Web of Science ®Google Scholar
• JiangY, ZhaoG, SongN, et al. Blockade of the C5a-C5aR axis alleviated lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7:77. doi:10.1038/s41426-018-0063-829691378
   PubMed Web of Science ®Google Scholar
• GiudiceV, PaglianoP, VatrellaA, et al. Combination of Ruxolitinib and Eculizumab for treatment of severe SARS-CoV-2-related acute respiratory distress syndrome: a controlled study. Front Pharmacol. 2020;11:857. doi:10.3389/fphar.2020.0085732581810
   PubMed Web of Science ®Google Scholar
• DiurnoF, NumisFG, PortaG, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24:404047. doi:10.26355/eurrev_202004_20875
   Web of Science ®Google Scholar
• SchönrichG, RafteryMJ. The PD-1/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol. 2019;9:207. doi:10.3389/fcimb.2019.0020731263684
   PubMed Web of Science ®Google Scholar
• ChenY, DiaoB, WangC, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). Front Immunol. 2020;11:827. doi:10.3389/fimmu.2020.0082732425950
   PubMed Web of Science ®Google Scholar
• JamillouxY, HenryT, BelotA, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020;19:102567. doi:10.1016/j.autrev.2020.10256732376392
   PubMed Web of Science ®Google Scholar
• VillarJ, ZhangH, SlutskyAS. Lung repair and regeneration in acute respiratory distress syndrome. Chest. 2019;155:587–594. doi:10.1016/j.chest.2018.10.02230392791
   PubMed Web of Science ®Google Scholar
• TeuwenLA, GeldhofV, PasutA, CarmelietP. COVID-19: the vasculature unleashed. Nat Rev Immunol. 2020;20:389–391. doi:10.1038/s41577-020-0343-032439870
   PubMed Web of Science ®Google Scholar
• YukselH, YilmazO, KaramanM, et al. Vascular endothelial growth factor antagonism restores epithelial barrier dysfunction via affecting zonula occludens proteins. Exp Ther Med. 2015;10:362–368. doi:10.3892/etm.2015.250226170963
   PubMed Web of Science ®Google Scholar
• PangJ, XuF, AondioG, et al. Efficacy and tolerability of bevacizumab in patients with severe Covid-19. Nat Commun. 2021;12:814. doi:10.1038/s41467-021-21085-833547300
   PubMed Web of Science ®Google Scholar
• LiY, ShiK, QiF, et al. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: a case-series study. Int J Infect Dis. 2021;103:507–513. doi:10.1016/j.ijid.2020.12.02333333254
   PubMed Web of Science ®Google Scholar
• ChenC, QiF, ShiK, et al. Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019. Clin Transl Med. 2020;10:e35. doi:10.1002/ctm2.3532508009
   PubMed Web of Science ®Google Scholar
• U.S. National Library of Medicine. MedlinePlus. Thalidomide. Available from: https://medlineplus.gov/druginfo/meds/a699032.html. Accessed 319, 2021.
   Google Scholar
• McClendonJ, JansingNL, RedenteEF, et al. Hypoxia-inducible factor 1α signaling promotes repair of the alveolar epithelium after acute lung injury. Am J Pathol. 2017;187:1772–1786. doi:10.1016/j.ajpath.2017.04.01228618253
   PubMed Web of Science ®Google Scholar
• Drug Information Portal. U.S. National Library of Medicine. Alprostadil. Available from: https://druginfo.nlm.nih.gov/drugportal/name/alprostadil. Accessed 319, 2021.
   Google Scholar
• HashimotoS, SanuiM, EgiM, et al. The clinical practice guideline for the management of ARDS in Japan. J Intensive Care. 2017;5:50.28770093
   PubMed Web of Science ®Google Scholar
• RussellJA, RoncoJJ, DodekPM. Physiologic effects and side effects of prostaglandin E1 in the adult respiratory distress syndrome. Chest. 1990;97:684–692. doi:10.1378/chest.97.3.6842306970
   PubMed Web of Science ®Google Scholar
• RicheldiL, Fernández PérezER, CostabelU, et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a Phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8:25–33. doi:10.1016/S2213-2600(19)30262-031575509
   PubMed Web of Science ®Google Scholar
• XuJ, XuX, JiangL, DuaK, HansbroPM, LiuG. SARS-CoV-2 induces transcriptional signatures in human lung epithelial cells that promote lung fibrosis. Respir Res. 2020;21:182. doi:10.1186/s12931-020-01445-632664949
   PubMed Web of Science ®Google Scholar
• ItoY, CorrellK, SchielJA, FiniganJH, PrekerisR, MasonRJ. Lung fibroblasts accelerate wound closure in human alveolar epithelial cells through hepatocyte growth factor/c-Met signaling. Am J Physiol Lung Cell Mol Physiol. 2014;307:L94–L105. doi:10.1152/ajplung.00233.201324748602
   PubMed Web of Science ®Google Scholar
• HamiltonJA. GM-CSF in inflammation. J Exp Med. 2020;217:E20190945.31611249
   PubMed Web of Science ®Google Scholar
• De LucaG, CavalliG, CampochiaroC, et al. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study. Lancet Rheumatol. 2020;2:e465–e473. doi:10.1016/S2665-9913(20)30170-332835256
   PubMedGoogle Scholar
• TemesgenZ, AssiM, ShwetaFNU, et al. GM-CSF neutralization with lenzilumab in severe COVID-19 pneumonia: a case-cohort study. Mayo Clin Proc. 2020;95:2382–2394.33153629
   PubMed Web of Science ®Google Scholar
• LangFM, LeeKMC, TeijaroJR, et al. GM-CSF-based treatments in COVID-19: reconciling opposing therapeutic approaches. Nat Rev Immunol. 2020;20:507–514. doi:10.1038/s41577-020-0357-732576980
   PubMed Web of Science ®Google Scholar
• RöslerB, HeroldS. Lung epithelial GM-CSF improves host defense function and epithelial repair in influenza virus pneumonia-a new therapeutic strategy? Mol Cell Pediatr. 2016;3:29. doi:10.1186/s40348-016-0055-527480877
   PubMedGoogle Scholar
• HeroldS, HoegnerK, VadászI, et al. Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome. Am J Respir Crit Care Med. 2014;189:609–611. doi:10.1164/rccm.201311-2041LE24579839
   PubMed Web of Science ®Google Scholar
• DranoffG, CrawfordAD, SadelainM, et al. Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. Science. 1994;264:713–716. doi:10.1126/science.81713248171324
   PubMed Web of Science ®Google Scholar
• KudlakKK, DeMuroJP, HannaAF, BremH. Acute lung injury following the use of granulocyte-macrophage colony-stimulating factor. Int J Crit Illn Inj Sci. 2013;3:279–281. doi:10.4103/2229-5151.12416824459628
   PubMedGoogle Scholar
• LiC, ZhaoH, WangB. Challenges for mesenchymal stem cell-based therapy for COVID-19. Drug Des Devel Ther. 2020;14:3995–4001. doi:10.2147/DDDT.S269407
   PubMed Web of Science ®Google Scholar
• CavalliG, De LucaG, CampochiaroC, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi:10.1016/S2665-9913(20)30127-232501454
   PubMedGoogle Scholar
• BalkhairA, Al-ZakwaniI, Al BusaidiM, et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: results of a prospective, open-label, interventional study. Int J Infect Dis. 2021;103:288–296. doi:10.1016/j.ijid.2020.11.14933217576
   PubMed Web of Science ®Google Scholar
• LandiL, RavagliaC, RussoE, et al. Blockage of interleukin-1β with canakinumab in patients with Covid-19. Sci Rep. 2020;10:21775. doi:10.1038/s41598-020-78492-y33311551
   PubMed Web of Science ®Google Scholar
• StrohbehnGW, HeissBL, RouhaniSJ, et al. COVIDOSE: a phase II clinical trial of low-dose tocilizumab in the treatment of noncritical COVID-19 pneumonia. Clin Pharmacol Ther. 2021;109:688–696. doi:10.1002/cpt.211733210302
   PubMed Web of Science ®Google Scholar
• FeldJJ, KandelC, BiondiMJ, et al. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial. Lancet Respir Med. 2021: S2213-2600(20)30566-X. doi:10.1016/S2213-2600(20)30566-X.
   Web of Science ®Google Scholar
• LiH, XiongN, LiC, et al. Efficacy of ribavirin and interferon-α therapy for hospitalized patients with COVID-19: a multicenter, retrospective cohort study. Int J Infect Dis. 2021;104:641–648. doi:10.1016/j.ijid.2021.01.05533515771
   PubMed Web of Science ®Google Scholar
• BaghaeiP, DastanF, MarjaniM, et al. Combination therapy of IFNβ1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of severe COVID-19 infected inpatients. Int Immunopharmacol. 2021;92:107329. doi:10.1016/j.intimp.2020.10732933412395
   PubMed Web of Science ®Google Scholar
• BronteV, UgelS, TinazziE, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130:6409–6416. doi:10.1172/JCI14177232809969
   PubMed Web of Science ®Google Scholar
• KaplanskiG, BontempsD, EsnaultP, et al. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: a pilot study. Autoimmun Rev. 2021;20:102726. doi:10.1016/j.autrev.2020.10272633326855
   PubMed Web of Science ®Google Scholar
• VoyseyM, Costa ClemensSA, MadhiSA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021. doi:10.1016/S0140-6736(21)00432-3
   Web of Science ®Google Scholar
• ZhangY, ZengG, PanH, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, Phase 1/2 clinical trial. Lancet Infect Dis. 2021;21:181–192. doi:10.1016/S1473-3099(20)30843-433217362
   PubMed Web of Science ®Google Scholar
• RichmondP, HatchuelL, DongM, et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:682–694. doi:10.1016/S0140-6736(21)00241-533524311
   PubMed Web of Science ®Google Scholar
• ChenP, NirulaA, HellerB, et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–237. doi:10.1056/NEJMoa202984933113295
   PubMed Web of Science ®Google Scholar
• MastellosDC, Pires da SilvaBGP, FonsecaBAL, et al. Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol. 2020;220:108598. doi:10.1016/j.clim.2020.10859832961333
   PubMed Web of Science ®Google Scholar